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The polarization of adipose tissue-resident macro-
phages toward the alternatively activated, anti-in-
flammatory M2 phenotype is believed to improve
insulin sensitivity. However, the mechanisms con-
trolling tissuemacrophage activation remain unclear.
Here we show that adipocytes are a source of Th2
cytokines, including IL-13 and to a lesser extent
IL-4, which induce macrophage PPARd/b (Ppard/b)
expression through a STAT6 binding site on its pro-
moter to activate alternative activation. Coculture
studies indicate that Ppard ablation renders macro-
phages incapable of transition to the M2 phenotype,
which in turns causes inflammation and metabolic
derangement in adipocytes. Remarkably, a similar
regulatory mechanism by hepatocyte-derived Th2
cytokines and macrophage PPARd is found to
control hepatic lipid metabolism. The physiological
relevance of this paracrine pathway is demonstrated
in myeloid-specific PPARd/ mice, which develop
insulin resistance and show increased adipocyte
lipolysis and severe hepatosteatosis. These findings
provide a molecular basis to modulate tissue-resi-
dent macrophage activation and insulin sensitivity.
INTRODUCTION
Adipose tissue has been recognized as an endocrine organ
modulating metabolic homeostasis (Qatanani and Lazar, 2007;
Rosen and Spiegelman, 2006). Within this microenvironment,
adipocytes secrete adipokines, including leptin, adiponectin,
and resistin, to control systemic lipid and glucose metabolism
(Qatanani and Lazar, 2007; Rosen and Spiegelman, 2006). In
contrast, adipose tissue-residentmacrophages (ATMs) are ama-
jor source of inflammatory mediators, such asmonocyte chemo-
attractant protein 1 (MCP-1) and tumor necrosis factor a (TNFa),
exerting direct and indirect effects on adipocyte function and in-
sulin sensitivity (Hotamisligil, 2006). A major role of ATMs in the
pathogenesis of metabolic diseases has been revealed in recent
studies. Increased macrophage infiltration in white adiposetissue (WAT) is found in obese states (Weisberg et al., 2003; Xu
et al., 2003). Following this observation, it has been suggested
that ATMs from lean animals show an alternatively activated,
M2 phenotype (Lumeng et al., 2007a), which is normally induced
byTh2cytokines, suchas interleukin-4 (IL-4) and IL-13. TheseM2
macrophages produce IL-10 to suppress inflammation (Gordon,
2003; Mantovani et al., 2004). High-fat feeding triggers the
recruitment ofmacrophages exhibitingmarkers of classic activa-
tion by Th1 cytokines, including interferon-g (IFN-g), IL-1b, and
TNFa, toWAT. TheseM1macrophages release proinflammatory
cytokines causing metabolic derangement. Although these find-
ings demonstrate a link between inflammation and metabolic
diseases, a critical question remaining to be answered is how
ATM activation is regulated and whether this M1/M2 phenotypic
switch is also relevant in macrophages residing in other metabol-
ically active tissues.
At the signaling level, inflammatory and metabolic processes
are intertwined and integral components of metabolic diseases
(Hotamisligil, 2006). For example, free fatty acids have been
shown to cause metabolic dysregulation through toll-like recep-
tor 4 (TLR4) (Shi et al., 2006),whereasproinflammatory cytokines,
such as TNFa, induce adipocyte lipolysis and inhibit insulin sig-
naling (Gasic et al., 1999; Hirosumi et al., 2002; Laurencikiene
et al., 2007; Souza et al., 1998). The c-Jun N-terminal kinase
(JNK) appears to be the common downstream effector targeted
by both signaling pathways. On the other hand, glycolysis is
known to provide the energy required to mount an inflammatory
response (Cramer et al., 2003; Kim et al., 2006; Seagroves
et al., 2001). More recently, lipid catabolism has been shown to
support the metabolic need during macrophage alternative acti-
vation, in which IL-4 activates PPARg coactivator 1b (PGC-1b)
and signal transducer and activator of transcription 6 (STAT6)
to inducegenes involved in fatty acid oxidation andmitochondrial
biogenesis (Vats et al., 2006). PGC-1b has also been proposed to
mediate IFN-g-induced mitochondrial reactive oxygen species
production through coactivating estrogen-related receptor
a (ERRa) in the control of genes encoding respiratory chain
machinery (Sonoda et al., 2007).
Peroxisome proliferator-activated receptor d (PPARd or
PPARb), together with PPARg andPPARa, constitutes a subfam-
ily within the nuclear receptor superfamily (Desvergne andWahli,
1999; Lee et al., 2003b; Reilly and Lee, 2008). PPARd has been
shown to transcriptionally regulate oxidative metabolism in
muscle and improve insulin sensitivity (Lee et al., 2006b; SchulerCell Metabolism 7, 485–495, June 2008 ª2008 Elsevier Inc. 485
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rophage, we have previously demonstrated that PPARd activa-
tion suppresses inflammation and induces genes in the fatty
acid catabolic program (Barish et al., 2008; Lee et al., 2003a,
2006a), suggesting that this receptormay function as ametabolic
regulator of alternative activation. In the current study, we eluci-
date a Th2 cytokine/PPARd signaling cascade that modulates
resident macrophage polarization. We find that adipocytes are
a source of Th2 cytokines, notably IL-13, which induces the ex-
pression of PPARd to induce ATM alternative activation. A similar
paracrine mechanism is found between hepatocyte-derived Th2
cytokines and macrophage PPARd in the liver. This signaling
cascade regulates metabolic homeostasis within metabolically
active tissues and may serve as a therapeutic target to treat
obesity-related metabolic syndrome.
RESULTS
Adipocyte-Conditioned Medium Induces Markers
of Alternative Activation
The balance between M1 andM2 ATMs is believed to contribute
to the onset of insulin resistance (Charo, 2007; Lumeng et al.,
2007a). However, the mechanism by which ATMs are polarized
has not been identified. We hypothesized that ATM activation
is modulated by factors released by adipocytes. To test this
hypothesis, we treated wild-type (WT) macrophages with condi-
tioned medium (CM) collected from fully differentiated 3T3-L1 or
3T3-F442A adipocytes. The proinflammatory genes Mcp-1 and
Tnfa were induced by 24 hr but declined after 48 hr (Figure 1A).
Unexpectedly, the M2 markers macrophage galactose N-ace-
tyl-galactosamine-specific lectin 1 and 2 (Mgl1 and Mgl2) were
also increased by CM, and the induction appeared to sustain
for 48 hr, indicating a switch from M1 to M2 status. In line with
this, 3T3-L1 adipocyte CM increased the activity of STAT6,
which is the key signaling effector of Th2 cytokines (Figure 1B),
and upregulated the expression of the Th2 cytokine receptors
Il-4r and IL-13ra1 (Figure 1C). These effects were not detected
in macrophages treated with preadipocyte CM (data not shown),
supporting our hypothesis that adipocyte factors may modulate
macrophage activation.
Recently, fatty acid catabolism and oxidative metabolism has
been shown to fuel alternative activation (Vats et al., 2006). We
found that genes encoding this metabolic program, including
Ppargc-1b (PGC-1b), Slc25a20, and Sdha, were increased by
3T3-L1 adipocyte CM (Figure 1C). Interestingly, the expression
of Ppard was also upregulated. As PPARd has been shown to
regulate fatty acid oxidation and oxidative metabolism, we
sought to determine whether PPARd mediated this phenotypic
switch. In fact, the ability of adipocyte CM to induce M2 signa-
ture geneswas severely reduced in PPARd/ (Ppard/) macro-
phages (Figure 1C). Flow cytometry analyses demonstrated that
the increase in cell-surface Mgl1 protein by CMwas abolished in
PPARd/ cells (see Figure S1C available online). In addition,
western blot analyses showed that in PPARd/ macrophages,
CM failed to increase STAT6 activity yet potentiated that of the
proinflammatory JNK (Figure 1B). Similar defects in M2 activa-
tion were also observed in PPARd/ macrophages treated
with 3T3-F442A adipocyte CM, IL-13, or IL-4 (Figure S1 and
data not shown). Collectively, these results suggest that adipo-486 Cell Metabolism 7, 485–495, June 2008 ª2008 Elsevier Inc.cyte factors activate PPARd in the macrophage to turn on alter-
native activation.
Adipocytes Are a Source of Th2 Cytokines
Macrophage alternative activation is mainly induced by IL-13
and IL-4, both of which activate STAT6 for signal transduction
(Gordon, 2003). Although these two cytokines are primarily
produced by type II T cells, the observation that adipocyte CM
increased STAT6 activity prompted us to examine whether adi-
pocytes are capable of producing Th2 cytokines. Remarkably,
the expression of Il-13was dramatically induced in fully differen-
tiated 3T3-L1 adipocytes compared to preadipocytes (Fig-
ure 2A). Similar results were obtained in differentiated human ad-
ipocytes (data not shown). Il-4was also induced in differentiated
3T3-L1 adipocytes but was undetectable in human adipocytes
under the same conditions. Since real-time PCR results did not
show the absolute expression level, enzyme-linked immunosor-
bent assays (ELISAs) were conducted to quantify IL-13 and IL-4
concentrations in CM and cell lysates. It was determined that the
concentration of IL-13 was 10-fold and 3- to 4-fold higher than
that of IL-4 in CM from 3T3 and primary adipocytes, respectively
(Figure 2B). In WAT, IL-13 concentration was 8-fold higher than
IL-4 concentration, and it could be readily detected by western
blot analyses (Figure 2A). Furthermore, recombinant IL-13 in-
creased macrophage Ppard expression (Figure 2C). These
data suggested that the effect of 3T3-L1 adipocyte CM was
mainly mediated by IL-13. To further verify this, macrophages
were treated with CM preincubated with IL-13-neutralizing anti-
body for 1 hr. IL-13 neutralization diminished the ability of CM to
induce markers of alternative activation, while it increased
Mcp-1 expression (Figure 2D). These results provide evidence
that ATM polarization may be modulated by adipocyte-derived
Th2 cytokines in a paracrine manner.
PPARd/ Macrophages Cause Adipocyte Dysfunction
Having established the potential role of adipocyte-derived Th2
cytokines and PPARd in ATM alternative activation, we sought
to examine how disruption of this pathway by Ppard ablation in
the macrophage affects WAT homeostasis. A coculture system
was employed to mimic the microenvironment of WAT, in which
macrophages were cultured in an insert on a semipermeable
membrane and differentiated 3T3-L1 adipocytes were grown in
the lower chamber of thewell.Wefirst examinedgeneexpression
in macrophages 48 hr after coculturing. Consistent with the re-
sults fromCMtreatment, theexpression ofM2markers, including
Mgl1,Mgl2, mannose receptor C type 2 (Mrc2), and Il-10, was in-
duced in WT macrophages (Figure 3A). In sharp contrast, Ppard
deletion led to upregulation of Il-6 and reduction of M2 genes.
These differences in gene expression were not mediated by de-
fects in macrophage differentiation, as levels of the macrophage
marker F4/80 (Emr1) remained unchanged between the two
genotypes. The differential expression of the anti-inflammatory
and proinflammatory cytokines Il-10 and Il-6 in WT and
PPARd/ macrophages indicated a potential feedback regula-
tion by the macrophage on adipocyte function. In fact, adipo-
cytes coincubated with PPARd/ macrophages exhibited
elevated expression of proinflammatory mediators, including
Mcp-1, Tnfa, and Il-6, with a concomitant increase in JNK signal-
ing, compared to adipocytes coincubatedwithWTmacrophages
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Adipocyte-Conditioned Medium on Induc-
tion of M2 Macrophage Markers
(A) The M2 markersMgl1 andMgl2 are induced in
macrophages treated with conditioned medium
(CM) collected from 3T3-L1 or 3T3-F442A adipo-
cytes. The expression of Mcp-1 and Tnfa also
increased 24 hr after CM treatment but declined
at 48 hr. Gene expression was determined by
real-time RT-PCR.
(B) Adipocyte CM increases STAT6 activity in the
macrophage. Protein lysates from wild-type (WT)
or PPARd/ macrophages were subjected to
western blot analyses. Phospho-STAT6 and phos-
pho-JNK (p-STAT6 and p-JNK) signals were used
to determine their respective activities. Total
STAT6 and total JNK (t-STAT6 and t-JNK) were in-
cluded as loading controls. The – and + signs indi-
cate absence or presence of CM treatment (48 hr),
respectively.
(C) The ability of 3T3-L1 adipocyte CM to activate
M2 genes is reduced in PPARd/ macrophages.
IL-4R, IL-4 receptor; IL-13Ra1, IL-13 receptor a1.
Values are expressed as means ± SEM. *p < 0.05
between  and + treatments within the same
genotype.(Figures 3B and 3C). This suggests that macrophage PPARdmay
dampen inflammation by switching on alternative activation,
which protects against adipocyte dysfunction caused by proin-
flammatory stimulants. In support of this idea, adipocytes cocul-
tured with WTmacrophages exhibited reduced levels of glucose
transporter 4 (Glut4) and insulin-stimulated glucose uptake.
However, the deregulated glucose metabolism was worsened
in adipocytes cocultured with PPARd/ macrophages (Fig-
ure 3C). These results indicate a critical role of alternative activa-
tion modulated by macrophage PPARd in the control of WAT
metabolic homeostasis.
Myeloid-Specific PPARd/ Mice Develop Insulin
Resistance
To examine the pathophysiological relevance of the observa-
tions in the coculture model, we generated myeloid-specific
PPARd knockout mice by crossing Ppardflox/flox mice (WT) to
lysozyme Cre mice (Mac-PPARd/). Genomic and real-time
RT-PCR analyses demonstrated that the deletion of exon 4 of
Ppard where the loxP sites flanked was nearly complete in mac-
rophages derived from bone marrow or isolated from the liver
and WAT but was not detected in other cell types such as
adipocytes, hepatocytes, and muscle fibers (Figure S2). In addi-
tion, the ability of the PPARd agonist GW501516 (Kang et al.,
2007; Oliver et al., 2001) to regulate target gene expression
was abolished in macrophages from Mac-PPARd/ mice.
Ppard gene deletion was also detected in other myeloid cells,
including dendritic cells and, to a lesser extent, neutrophils
(Figure S2). These mice showed no apparent developmental
phenotype.When fed a high-fat diet to induce obesity and metabolic
dysregulation, Mac-PPARd/ mice gained more weight than
control animals (Figure S3A). Interestingly, the ratio of WAT to
bodyweight was decreasedwhile the ratio of liver to bodyweight
was increased in Mac-PPARd/mice (Table S1). Glucose toler-
ance test (GTT) showed no difference because Mac-PPARd/
mice exhibited increased insulin secretion both at baseline and
during GTT, a defect found before full-blown diabetes (Fig-
ure 4A). Insulin tolerance test (ITT) further verified that these
mice were insulin resistant compared to WT controls. To deter-
mine which metabolically active tissues contributed to the
observed phenotype, we examined insulin signaling in WAT,
liver, and muscle after an acute insulin injection. Impaired insulin
signal transduction, determined by insulin-stimulated Akt phos-
phorylation, was found in WAT but not liver or muscle of Mac-
PPARd/ mice (Figure 4B; Figures S3B and S3C). Insulin-stim-
ulated tyrosine phosphorylation of insulin receptor b (IRb) was
also dramatically reduced in WAT. In addition, the level of phos-
pho-STAT6 was decreased, whereas JNK activity was increased
(Figure 4D). These data demonstrate that macrophage Ppard
ablation disrupts WAT homeostasis leading to adipocyte insulin
resistance, verifying the model derived from in vitro studies.
Myeloid Ppard Gene Deletion Causes Tissue
Inflammation and Dysfunction
To further characterize the glucose metabolism phenotypes and
the altered tissue mass, histological analyses of WAT and liver
were performed on the high-fat-fed cohort. Intriguingly, Mac-
PPARd/WAT showed the presence of many small adipocytes
surrounded by macrophages (Figure 5A). Examination ofCell Metabolism 7, 485–495, June 2008 ª2008 Elsevier Inc. 487
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genes encoding GLUT4 and perilipin, a lipid droplet-coating pro-
tein controlling lipid storage and lipolysis (Londos et al., 2005),
was downregulated, whereas genes encoding lipogenesis (fatty
acid synthase [Fas]), fatty acid oxidation (carnitine palmitoyl-
transferase 1 [Cpt1]), and adipokines (leptin and adiponectin)
were unaffected (Figure 5B). Consistent with the coculture stud-
ies, the M2markersMgl1,Mgl2, andMrc2were suppressed and
the proinflammatory mediators Mcp-1, Tnfa, and Il-6 as well as
the pan-macrophage marker F4/80 were upregulated in WAT of
Mac-PPARd/ mice (Figures 5C and 5D). Furthermore, TNFa
protein levels as determined by ELISA were higher, whereas IL-
13 and IL-4 levels were similar in Mac-PPARd/WAT, suggest-
ing that the changes in inflammatory statuswere not due to differ-
ences in the production ofWAT-derived Th2 cytokines (Figure 5E
and data not shown). Since TNFa has been shown to increase li-
polysis through perilipin downregulation (Laurencikiene et al.,
2007), we sought to determine whether WAT of Mac-PPARd/
mice exhibited increased lipolysis. Primary adipocytes were iso-
lated from high-fat-fed mice and subjected to stimulation with
isoproterenol, a b-adrenergic receptor agonist. We found that
adipocytes from Mac-PPARd/ mice exhibited a >2-fold
increase in basal and isoproterenol-stimulated lipolysis
(Figure 5F). These findings suggest that the reduction in adipo-
cyte size andWAT to bodyweight ratio bymyeloidPparddeletion
may result from deregulated adipocyte lipolysis.
Figure 2. Adipocytes Produce Th2 Cyto-
kines
(A) The expression of Il-13 and Il-4 is induced dur-
ing 3T3-L1 adipocyte differentiation. Left: gene
expression was determined by real-time PCR at
days 0, 4, and 7 (d0, d4, and d7) of the differentia-
tion process. Right: IL-13 protein in 3T3-L1 adipo-
cyte (Ad) and white adipose tissue (WAT) lysates
(100 mg) was detected by western blotting. Re-
combinant IL-13 (rIL-13; 60 ng) was included as
a control.
(B) Quantification of Th2 cytokines in CM and ly-
sates from 3T3-L1, 3T3-F442A, and primary adi-
pocytes and WAT by ELISA. Pre CM, preadipo-
cyte CM.
(C) IL-13 induces PPARd expression in macro-
phages as determined by real-time PCR. Cells
were administered IL-13 (20 ng/ml) for 24 hr.
(D) Preincubation with IL-13-neutralizing antibody
abolishes the ability of CM to induce alternative ac-
tivation. 3T3-L1 adipocyte CM was preincubated
with an IL-13-neutralizing antibody (IL-13 Ab) or
control IgG 1 hr prior to treatment ofmacrophages.
Values are expressed as means ± SEM. *p < 0.05
between CM treatment and control; **p < 0.05
between IgG and IL-13 Ab.
Assessment of liver samples revealed
that hepatosteatosis was more profound
in Mac-PPARd/ mice compared to WT
controls,which correlatedwellwith the in-
creased hepatic triglyceride content
(Figure 6A). In line with this observation,
the expression of lipogenic genes (Fas
and Acc2) was induced in livers of Mac-PPARd/mice. In con-
trast, oxidative metabolism genes remained unchanged
(Figure 6B). Interestingly, Il-1b and F4/80 were upregulated,
and M2 markers, including arginase 1 (Arg1) and Mrc2, were
downregulated. These results prompted us to examine whether
a similar Th2 cytokine/PPARd regulatory mechanism between
hepatocytes and resident macrophages (e.g., Kupffer cells)
might exist and regulate hepatic lipid metabolism. In fact, we de-
tected IL-13 and IL-4 in liver and hepatocyte lysates, and the
IL-13 concentration appeared to be higher than that of IL-4
(Figure 6C). In addition, M2 markers were induced in WT macro-
phages cocultured with hepatocytes. This induction was dimin-
ished in PPARd/ macrophages (Figure 6D). On the other
hand, hepatocytes cocultured with PPARd/ macrophages
showed increased Acc2 expression (Figure 6E), which was also
observed in livers ofMac-PPARd/mice.ACC2 is known to sup-
press fatty acid catabolism (Abu-Elheiga et al., 2001). As ex-
pected from elevated ACC2 activity, hepatocytes cocultured
with PPARd/macrophages had reduced fatty acid b-oxidation
(Figure 6E, insert), indicating that the increase in hepatic lipid ac-
cumulation in Mac-PPARd/mice could be due to increased li-
pogenesis and reduced fatty acid catabolism. Collectively, these
data suggest that the signaling cascade involving tissue-derived
Th2 cytokines and macrophage PPARd plays a critical role in
modulating inflammation and maintaining metabolic homeosta-
sis in metabolically active sites such as the liver and WAT.488 Cell Metabolism 7, 485–495, June 2008 ª2008 Elsevier Inc.
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Activation by PPARd
Results presented earlier indicate that Th2 cytokines upregulate
PPARd to modulate macrophage alternative activation (Figure 1
and Figure 2). We sought to determine whether PPARd is a direct
target of Th2 cytokines. Analysis of a 2 kb promoter region of
Ppard had identified a putative STAT6 binding site. Reporter as-
says conducted in the RAW264.7 macrophage cell line verified
that Ppard promoter activity could be induced by IL-13 and
that this induction was abolished when the STAT6 binding site
wasmutated (Figure 7A), indicating that Th2 cytokine/STAT6 sig-
naling controls PPARd expression. To understand the molecular
mechanism through which PPARd regulates M2 gene expres-
sion, Mgl1 promoter activity was examined. Interestingly, re-
porter assays showed that the basal and IL-13-induced Mgl1
promoter activity was greatly enhanced by cotransfection of
expression vectors for PPARd and the obligate heterodimer
partner retinoid X receptor a (RXRa) (Figure 7B), which was
further increased by the addition of the PPARd agonist
GW501516. Consistent with the in vitro result, GW501516 and
IL-13 synergistically upregulated Mgl1 in WT macrophages
(Figure 7C). Putative DNA-binding elements for PPARd and
STAT6 could be found in the 2 kb regulatory region used for
reporter assays (data not shown), suggesting that in addition to
controlling PPARd expression, Th2 cytokine signalingmay cross-
talk with PPARd on theMgl1 promoter. Similarly, GW501516 and
adipocyte CM had a synergistic effect onMgl1 upregulation, and
the ligand effect was completely lost in PPARd/macrophages
(Figure 7D).
PPARg has previously been shown to modulate M2 activation
(Bouhlel et al., 2007; Odegaard et al., 2007), raising the question
ofwhether PPARg activation could rescue the defect in PPARd/
macrophages. Rosiglitazone, a PPARg agonist, increased the
basal level of Mgl1 (Figure 7D). However, it minimally affected
CM-induced Mgl1 expression in PPARd/ macrophages.
Furthermore, the reduction in the ability of adipocyte CM or
IL-13 to upregulate Mgl1 was similar between PPARd/ and
PPARd/g/ double-knockout macrophages, indicating that
PPARd plays a predominant role in the transcriptional control
of alternative activation (Figure 7E). In summary, these findings
suggest that PPARd functions as an effector of Th2 cytokines
whose activation is required for the upregulation of M2 gene
expression.
DISCUSSION
This study uncovers two unexpected sources of Th2 cytokines,
adipocytes and hepatocytes. This finding provides a molecular
mechanism through which resident macrophage activation is
modulated. Our results further show that PPARd is induced by
Th2 cytokines to control the transcriptional program of alterna-
tive activation in the macrophage. The subsequent phenotypic
Figure 3. Assessment of the Role of Alter-
native Activation Regulated byMacrophage
PPARd in WAT Homeostasis Using a Cocul-
ture Model
(A) PPARd plays an important role in macrophage
alternative activation induced by adipocyte-
derived Th2 cytokines. A coculture system was
established to mimic the WAT microenvironment,
in which macrophages were cultured on an insert
on a semipermeable membrane and differentiated
3T3-L1 adipocytes were grown in the lower cham-
ber of the well. Gene expression in macrophages
was determined by real-time PCR 48 hr after co-
culturing with adipocytes. Mgl1, Mgl2, Mrc2, and
Il-10 are M2 markers; F4/80 (Emr1) is a macro-
phage marker included as a control. The – and +
signs indicate absence or presence of adipocyte
(ad) coculture, respectively.
(B) Adipocytes cocultured with PPARd/ macro-
phages express higher levels of proinflammatory
mediators. Two days after coculturing with macro-
phages, adipocytes were harvested and gene
expression was determined by real-time PCR.
(C) Adipocytes cocultured with PPARd/ macro-
phages exhibit reduced glucose transporter 4
(Glut4) expression and insulin-stimulated glucose
uptake. The expression of Glut4 in control adipo-
cytes (–) or adipocytes cocultured with WT or
PPARd/ macrophages was determined by
real-time PCR and western blotting. The glucose
uptake assay was performed using radioactive
2-deoxyglucose. mf, macrophage; p-JNK, phos-
pho-JNK; t-JNK, total JNK.
Values are expressed as means ± SEM. *p < 0.05
between WT and PPARd/ macrophages.Cell Metabolism 7, 485–495, June 2008 ª2008 Elsevier Inc. 489
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(A) Hyperinsulinemia and insulin resistance in Mac-PPAR/mice fed a high-fat diet. Glucose tolerance test (GTT) (left panel), insulin production during the GTT
(middle panel), and insulin tolerance test (ITT) (right panel) were conducted in male mice (n = 7) after 4 months of high-fat diet.
(B and C) Defective insulin signaling in WAT of Mac-PPARd/ mice. Mice were administered 5 U insulin/kg body weight through the portal vein. Tissues were
collected right before or 5 min after injection. Insulin-stimulated Akt phosphorylation (p-Akt) (B) and IRb tyrosine phosphorylation (C) were determined in WAT
lysates from five individual WT or Mac-PPARd/ mice by western blot analysis. IRb was immunoprecipitated, followed by immunoblotting with anti-phospho-
tyrosine (p-Tyr-IRb) and anti-IRb antibodies. The level of insulin-stimulated phosphorylation was quantified and normalized to that of total protein to obtain fold
changes. Similar results were obtained using actin for normalization. t-Akt, total Akt.
(D)Western blot analyses demonstrating increased JNK and decreased STAT6 signaling inWAT ofMac-PPARd/mice. p-JNK and p-STAT6, phospho-JNK and
phospho-STAT6; t-JNK and t-STAT6, total JNK and total STAT6.
Values are expressed as means ± SEM. *p < 0.05 between WT and Mac-PPARd/ mice.switch to the M2 phenotype plays an important role in dampen-
ing inflammation within WAT and the liver, thereby providing
protection against insults from inflammatory stimulants. The
physiological relevance of this pathway is demonstrated in
myeloid-specific PPARd/ mice, which exhibit adipocyte
dysfunction and insulin resistance as well as hepatosteatosis.
Several lines of evidence support the notion that tissue-de-
rived Th2 cytokines are biological active and metabolically rele-
vant. First, conditioned medium collected from 3T3 adipocytes,
which mainly contains IL-13, increased STAT6 activity and the
expression of M2 markers. This effect was inhibited by an
IL-13-neutralizing antibody. In addition, IL-13 and IL-4 protein
could be detected in lysates from primary adipocytes and hepa-
tocytes as well as from WAT and liver, although IL-4 levels490 Cell Metabolism 7, 485–495, June 2008 ª2008 Elsevier Inc.appeared to be severalfold lower. The production of Th2 cyto-
kines by adipocytes and hepatocytes could be considered a
regulatory mechanism to prevent uncontrolled inflammation
(Figure 7F), as macrophages in WAT and liver are prone to acti-
vation by inflammatory mediators, including free fatty acids. The
activated macrophages, in turn, release cytokines, such as
TNFa, IL-1b, and IL-6, which cause metabolic deregulation. In
the macrophage, the signaling of Th2 cytokines is transduced
through STAT6 and PPARd. While some fatty acid species trig-
ger inflammation, others may serve as endogenous ligands to
activate PPARd to turn on alternative activation.
In support of the proposed model, high-fat-fed myeloid-spe-
cific PPARd/ mice showed increased M1 and decreased M2
markers in WAT and liver. This results in lipolysis and insulin
Cell Metabolism
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(A) Histological analyses of WAT sections (hematoxylin and eosin [H&E] staining) from high-fat-fed WT andMac-PPARd/mice. Mac-PPARd/WAT contained
small adipocytes that were surrounded by macrophages.
(B) Analyses of metabolic gene expression in WAT by real-time PCR. IRS1, insulin receptor substrate 1; HSL, hormone-sensitive lipase; FAS, fatty acid synthase;
CPT1, carnitine palmitoyltransferase 1.
(C) M2 markers are downregulated in WAT of Mac-PPARd/ mice. M2 gene expression was determined by real-time PCR and normalized to F4/80.
(D) WAT of Mac-PPARd/ mice exhibits elevated inflammatory gene expression. Gene expression was determined by real-time PCR.
(E) Determination of TNFa and IL-13 protein concentration in WAT by ELISA.
(F) Increased lipolysis in primary adipocytes fromMac-PPARd/mice. The rate of lipolysis was determined by glycerol release at baseline or upon isoproterenol
stimulation.
Values are expressed as means ± SEM. *p < 0.05 between WT and Mac-PPARd/ mice.resistance in adipocytes. These defects are likely mediated by
elevatedTNFa, as TNFahasbeenshown to interferewith glucose
metabolism by downregulation of GLUT4, to inhibit insulin sensi-
tivity through JNKactivation (Hirosumi et al., 2002; Lumeng et al.,
2007b;Ruanet al., 2002), and tocause lipolysis by suppressionof
perilipin expression (Laurencikiene et al., 2007). In the liver, the
proinflammatory status increases lipogenesis. The induction of
ACC2 further suppresses fatty acid catabolism. The combined
effect leads to increased triglyceride accumulation. Although
insulin signaling in the liver showed no difference at the time of
examination, the deregulated fat metabolism will likely worsen
hepatic insulin resistance inMac-PPARd/mice at a later stage.
We did not observe changes in inflammatory or metabolic genes
in muscle (Figure S3 and data not shown). This was not unex-
pected, as we were unable to detect an appreciable amount of
IL-13 or IL-4 by ELISA in muscle (data not shown). Themetabolic
phenotype of Mac-PPARd/mice was less profound on a chow
diet. These mice showed mild glucose intolerance and insulin
resistance compared to WT controls as determined by GTT and
ITT (Figures S4A and S4B). There was no significant difference
in the expression of M1 and M2 markers in WAT, liver, or muscle
(data not shown). However, the presence of adipocytes sur-
rounded by macrophages and hepatic lipid accumulation wereobserved in Mac-PPARd/mice (Figures S4C and S4D). These
results suggest that in the unchallenged, lean state, other signal-
ing pathways are capable of maintaining basal M2 gene expres-
sion. Nevertheless, it appears that even a minor shift in the resi-
dent macrophage polarization is sufficient to induce metabolic
dysregulation.
One of the potential signaling pathways known to modulate
M2 activation is through PPARg, which causes insulin resistance
in multiple tissues when deleted in myeloid cells (Hevener et al.,
2007; Odegaard et al., 2007). However, our data suggest that
PPARg cannot compensate for the loss of PPARd. In fact,
PPARd/g/ macrophages show a defect in Mgl1 expression
similar to that of PPARd/ macrophages. A similar result was
seen in Mgl2 expression (data not shown). It is possible that
PPARg plays a predominant role in circulating monocytes, as it
has been shown that PPARg activation inducesmonocyte differ-
entiation into M2 macrophages but does not affect resting mac-
rophages (Bouhlel et al., 2007). Alternatively, PPARd may act as
a competent factor for Th2 cytokine-induced M2 gene expres-
sion. Evidence supporting this idea comes from the observation
that the ability of IL-13 to upregulate Mgl1 promoter activity is
highly dependent on PPARd (Figure 7B). In addition, STAT6
activation and IL-4Ra induction by Th2 cytokines are diminishedCell Metabolism 7, 485–495, June 2008 ª2008 Elsevier Inc. 491
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Macrophage PPARd Regulates Metabolic HomeostasisFigure 6. Mac-PPARd/ Mice Exhibit Severe Hepatic Steatosis
(A) Histological analyses of liver sections (H&E staining) from high-fat-fed WT and Mac-PPARd/ mice. Livers of Mac-PPARd/ mice contained larger lipid
droplets. Hepatic lipid content was determined by enzymatic assays and normalized to protein content.
(B) Analyses of metabolic and inflammatory gene expression in the liver by real-time PCR. ACC2, acetyl-CoA carboxylase 2; SREBP, sterol regulatory element-
binding protein 1c; AOX, acetyl-CoA oxidase.
(C) Hepatocytes are a source of Th2 cytokines. IL-13 and IL-4 concentrations in lysates of isolated hepatocytes and liver were determined by ELISA.
(D) M2 markers are induced in macrophages cocultured with primary hepatocytes. Experiments were conducted similar to those in the macrophage-adipocyte
coculture in Figure 3. The induction ofMgl1 andMgl2was diminished in PPARd/macrophages. The – and + signs indicate absence or presence of hepatocyte
coculture, respectively.
(E) Hepatocytes cocultured with PPARd/ macrophages have increased Acc2 expression and reduced fatty acid oxidation. Inset: the rate of fatty acid
b-oxidation as determined by 3H2O production from
3H-labeled fatty acids.
Values are expressed as means ± SEM. *p < 0.05 between WT and Mac-PPARd/ mice/cells.in PPARd/ macrophages (Figure 1) but remain intact in
PPARg/ macrophages (Odegaard et al., 2007). PPARd may
do so by controlling the expression of PGC-1b (Figure 1C;
Figure S1A), which has been shown to coactivate STAT6 (Vats
et al., 2006) and may also be required for the full transcriptional
activity of PPARg. However, we cannot rule out the possibility
that PPARd and PPARg control different subsets of M2 genes.
Adipocytes and hepatocytes are unique in their capability of
producing both Th1 and Th2 cytokines. The balance in the pro-
duction of these two counter forces therefore determines the po-
larization of macrophages residing in WAT and liver. The current492 Cell Metabolism 7, 485–495, June 2008 ª2008 Elsevier Inc.study identifies PPARd as a potential drug target to modulate tis-
sue macrophage activation and insulin sensitivity. Future studies
investigating how Th1 and Th2 cytokine production is controlled
in adipocytes and hepatocytes may also reveal additional thera-
peutic pathways to combat obesity-related metabolic diseases.
EXPERIMENTAL PROCEDURES
Animal Experiments
The Ppard and Pparg floxed allele was generated as described previously
(Barak et al., 1999, 2002). Ppard f/f, Ppard/g f/f, and lysozyme-Cre transgenic
Cell Metabolism
Macrophage PPARd Regulates Metabolic HomeostasisFigure 7. Synergistic Regulation of M2 Gene Expression by IL-13 and PPARd
(A) Ppard promoter activity is induced by IL-13 through a STAT6 binding site. A luciferase (luc) reporter driven by the mouse Ppard promoter (upper panel) was
transfected into RAW264.7 cells. IL-13 was administered at 40 ng/ml. The transcriptional initiation site was designated as +1, and the putative and mutated
STAT6 binding sites on the Ppard promoter are indicated in the WT and mutant sequences, respectively. STAT6 mutant, Ppard promoter reporter with mutated
STAT6 binding site; RLU, relative luciferase units. *p < 0.05 between IL-13 and vehicle treatment.
(B) TheMgl1 promoter is regulated by PPARd and IL-13. An Mgl1 promoter reporter was transfected into RAW264.7 cells together with either control vector or
expression vectors for PPARd and RXRa. Cells were treated with IL-13 (40 ng/ml) and/or a PPARd agonist, GW501516 (0.1 mM). *p < 0.05 versus vehicle-treated
control.
(C) Cotreatment with IL-13 and GW501516 synergistically inducesMgl1 expression in macrophages.Mgl1 expression was determined 48 hr after treatments by
real-time PCR.
(D) PPARg activation could not compensate for PPARd function in alternative activation. Mgl1 expression was measured in WT and PPARd/ macrophages
treated with the PPARg agonist rosiglitazone (rosi; 1 mM), GW501516, 3T3-F442A (F442A) adipocyte CM, or combinations thereof.
(E) PPARd/g/ and PPARd/ macrophages show a similar reduction in F442A adipocyte CM and IL-13-stimulated Mgl1 expression.
(F) Model for the role of macrophage PPARd in metabolic homeostasis. Macrophages in WAT and the liver are prone to activation by stimulants, such as Th1
cytokines and free fatty acids. As a regulatory mechanism, adipocytes and hepatocytes produce Th2 cytokines to dampen inflammation. The signaling of
Th2 cytokines is amplified through the activation of STAT6 and induction of PPARd. Fatty acids also serve as ligands to activate PPARd to control the expression
of M2 genes as well as genes encoding oxidative metabolism, including Ppargc-1b (PGC-1b), which is required for STAT6 coactivation. High-fat feeding or Ppard
gene deletion disrupts this homeostasis, leading to metabolic dysfunction in WAT and liver.
Values are expressed as means ± SEM.Cell Metabolism 7, 485–495, June 2008 ª2008 Elsevier Inc. 493
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Macrophage PPARd Regulates Metabolic Homeostasismice (obtained from The Jackson Laboratory) were on the C57BL/6 back-
ground. The chow diet study was conducted in 9-month-old male mice (n = 5).
For the high-fat feeding study, 3-month-old male mice (n = 7) were placed on
a high-fat, high-carbohydrate diet (F3282, Bio-Serv) for 4 months. GTT was
performed by injecting 1 g glucose/kg body weight into the peritoneum. Blood
glucose was measured before and after injection at the time points indicated
using a OneTouch glucose monitoring system (LifeScan). ITT was conducted
similarly by injecting 0.7 U insulin/kg body weight. For determining insulin sig-
naling in vivo, insulin (5 U/kg body weight) was injected through the portal vein.
A sample of liver, epididymal fat pad, and muscle was collected before and
5 min after insulin injection and rapidly stored in liquid nitrogen. The metabolic
phenotypes were reproduced in a second cohort (n = 5–7; data not shown).
Serum and hepatic triglyceride, free fatty acids, and total cholesterol were
measured using commercially available kits (Wako Chemicals and Thermo
DMA). Insulin levels were measured using ELISA kits (Linco). All histology
was performed at the Dana-Farber/Harvard Cancer Center Research Pathol-
ogy Cores, which also provided preliminary histological assessment by a
pathologist. Statistical analysis was performed using Student’s t test (two-
tailed). Values are presented as means ± SEM. p < 0.05 was considered
significant. All animal studies were approved by the Harvard Medical Area
Standing Committee on Animals.
Cell Culture
Bone marrow-derived macrophages were differentiated in L929 conditioned
medium as described previously (Lee et al., 2003a). PPARd/ and PPARd/
g/macrophages were obtained from Mac-PPARd/ and Mac-PPARd/g/
mice, respectively. Experiments were conducted in low-glucose DMEM,
10% FBS. 3T3-L1 and 3T3-F442A adipocytes were differentiated in a cocktail
containing insulin, isobutylmethylxanthine, and dexamethasone based on
a standard protocol (Tontonoz et al., 1994). Conditioned medium was col-
lected from fully differentiated adipocytes, which had been cultured in
DMEM, 10% FBS in the absence of differentiation cocktail for 2 days. Goat
anti-mouse IL-13 neutralization antibody was added to conditioned medium
based on the ND50 provided by the manufacturer (R&D Systems). Goat IgG
was added to the same concentration in the control experiment, which had
no effect on macrophage activation at the dose used. For coculture experi-
ments, macrophages were grown in an insert and placed into a well containing
adipocytes or hepatocytes (Transwell, Corning). Two days after coculturing,
macrophages and adipocytes/hepatocytes were collected separately for var-
ious assays. The transmigration of macrophages from the upper to the lower
compartment was minimal as determined by the expression of F4/80 in adipo-
cytes/hepatocytes. Hepatocytes were isolated by collagenase perfusion.
In Vitro Metabolic Assays
The glucose uptake assay was conducted using 2-[3H]deoxy-D-glucose in
Krebs-Ringer bicarbonate HEPES (KRBH) buffer. Cells were prestimulated
with 100 nM insulin for 10 min, followed by the addition of radioactive glucose.
Glucose uptake was determined within 20 min and normalized to protein con-
tent. For lipolysis, primary adipocytes were isolated by collagenase digestion
and filtered through 250 mMnylonmesh. Cells were suspended in KRBH buffer
with or without 10 mM isoproterenol for 1 hr. The rate of lipolysis was deter-
mined by glycerol release in the medium. Fatty acid oxidation was determined
as described previously (Lee et al., 2006a).
Expression Analyses
For gene expression analyses, SYBR green-based real-time RT-PCR reac-
tions were conducted as described previously using 36b4 levels as loading
controls to obtain relative expression levels (Lee et al., 2006b). For western
blot analyses, tissue or cell lysates were prepared in a buffer containing prote-
ase and phosphatase inhibitors. To determine tyrosine phosphorylation of IRb,
WAT lysates were first immunoprecipitated with an anti-IRb antibody, followed
by immunoblotting with an anti-phosphotyrosine antibody or total IRb anti-
body. Antibodies against Akt, JNK, STAT6, and phosphotyrosine were pur-
chased from Cell Signaling, and antibodies against IRb, GLUT4, and actin
were purchased from Santa Cruz. IL-13 and IL-4 antibodies and ELISA kits
were obtained from R&D Systems. For reporter assays, a 2 kb fragment
containing either the mouse Ppard or Mgl1 promoter region was cloned into
pGL3-Basic vector (Promega). Cotransfection was conducted in RAW264.7494 Cell Metabolism 7, 485–495, June 2008 ª2008 Elsevier Inc.cells in a 48-well format using the dual-luciferase system (Promega). Both
mouse PPARd and human RXRa expression vectors were under the control
of a CMV promoter. Concentrations used were: GW501516, 0.1 mM; rosiglita-
zone, 1 mM; IL-13, 40 ng/ml.
SUPPLEMENTAL DATA
Supplemental Data include Supplemental Experimental Procedures, one
table, and four figures and can be found with this article online at http://
www.cellmetabolism.org/cgi/content/full/7/6/485/DC1/.
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